Clinical Pharmacokinetics

, Volume 56, Issue 6, pp 679–681

Erratum to: A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir

  • Matt S. Anderson
  • Sauzanne Khalilieh
  • Ka Lai Yee
  • Rachael Liu
  • Li Fan
  • Matthew L. Rizk
  • Vedangi Shah
  • Azra Hussaini
  • Ivy Song
  • Lisa L. Ross
  • Joan R. Butterton
Erratum
  • 489 Downloads

1 Erratum to: Clin Pharmacokinet DOI 10.1007/s40262-016-0458-4

Figures 2 and 3, and their corresponding legends were incorrect and were corrected in this erratum.

Figures 2 and 3 should appear as follows:
Fig. 2

Individual analyte parameter ratios for dolutegravir (a) and doravirine (b) with geometric mean ratios and 90% confidence intervals following multiple-dose administration with and without the additional treatment [doravirine and dolutegravir, respectively (per-protocol population)]. AUC0–24 area under the plasma concentration–time curve from dosing to 24 h post-dose, C24 concentration 24 h post-dose, Cmax maximum concentration

Fig. 3

Arithmetic mean steady-state doravirine plasma concentration profile with and without co-administration with dolutegravir: a linear scale (±SD) and b semi-log scale, SD standard deviation

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Matt S. Anderson
    • 1
  • Sauzanne Khalilieh
    • 1
  • Ka Lai Yee
    • 1
  • Rachael Liu
    • 1
  • Li Fan
    • 1
  • Matthew L. Rizk
    • 1
  • Vedangi Shah
    • 1
  • Azra Hussaini
    • 2
  • Ivy Song
    • 3
  • Lisa L. Ross
    • 4
  • Joan R. Butterton
    • 1
  1. 1.Merck & Co., Inc.KenilworthUSA
  2. 2.PAREXELBaltimoreUSA
  3. 3.GlaxoSmithKlineResearch Triangle ParkUSA
  4. 4.ViiV HealthcareResearch Triangle ParkUSA

Personalised recommendations